Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept T&E regimen in nAMD
NCT02581891Phase 4Completed
- Sponsor
- Bayer
- Start
- Nov 2015
- Primary completion
- Apr 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 4 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Bayer. Started Nov 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02581891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581891.